Financière de Tubize S.A.
TUB
Clasificación en acciones
#2220
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Precio por acción
$203.04
Capitalización bursátil
$9.04B
Cambio (1 día)
-7.47%
Cambio (1 año)
-25.36%
País
BE
Comercio Financière de Tubize S.A. (TUB)
Categoría
Healthcare
Ganancias de Financière de Tubize S.A. (TUB)
Ganancias en Jun 2026 TTM: $116.73M
Secondo gli ultimi rapporti finanziari di Financière de Tubize S.A., gli utili attuali della società sono $116.73M. Nel 2023, la società ha registrato un utile di $97.45M, un aumento con respecto a agli utili del 2022, che erano di $91.36M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Financière de Tubize S.A. desde 2003 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $116.73M | 24.50% |
| 2024 | $93.76M | -3.79% |
| 2023 | $97.45M | 6.66% |
| 2022 | $91.36M | -3.90% |
| 2021 | $95.07M | -70.04% |
| 2020 | $317.28M | -0.32% |
| 2019 | $318.31M | -2.86% |
| 2018 | $327.69M | 2.60% |
| 2017 | $319.38M | 68.35% |
| 2016 | $189.71M | -16.83% |
| 2015 | $228.09M | 209.22% |
| 2014 | $73.76M | -15.46% |
| 2013 | $87.25M | -16.53% |
| 2012 | $104.53M | 15.02% |
| 2011 | $90.88M | 221.98% |
| 2010 | $28.23M | -87.95% |
| 2009 | $234.25M | -15,867.73% |
| 2008 | $-1.49M | -102.49% |
| 2007 | $59.74M | -90.49% |
| 2006 | $628.45M | 78.57% |
| 2005 | $351.93M | 105.84% |
| 2004 | $170.97M | 14.90% |
| 2003 | $148.80M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 4,418.76% |
US
|
|
| $-3.09B | -2,744.49% |
US
|
|
| $-4.02B | -3,540.48% |
AU
|
|
| $1.95B | 1,571.03% |
NL
|
|
| - | - |
CH
|
